The 2026 USA finalists nominated for “Best Startup” have been announced.  Paradigm Therapeutics has been selected as a finalist for the prestigious 2026 Prix Galien USA Award in the Start-Up category! Often called the “Nobel Prize of biopharmaceutical research,” this honor recognizes groundbreaking innovation in the life sciences. For us, this nomination highlights our unwavering […]

Please watch this video prepared ahead of Prix Galien gala:

The Post and Courier recently published a feature on Dr. Robert Ryan and the groundbreaking work happening at Paradigm Therapeutics. The article explores the journey behind SD-101, a topical therapy showing promise for patients with Epidermolysis Bullosa (EB), and the personal story that continues to drive the company’s mission forward.

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S.C., June 18, 2025 /PRNewswire/ – Paradigm Therapeutics, Inc., a biopharmaceutical company, […]

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. Mt Pleasant, S.C. (May 6, 2025) — Paradigm […]

‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal […]